MAYO CLINIC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1889-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mayoclinic.org
Clinical Trials
3.1k
Trial Phases
6 Phases
Drug Approvals
4
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (2314 trials with phase data)• Click on a phase to view related trials
Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors, MBRT1 Trial
- Conditions
- Metastatic Malignant Skin NeoplasmMetastatic Malignant Soft Tissue NeoplasmRecurrent Malignant Skin NeoplasmRecurrent Malignant Soft Tissue NeoplasmSkin NeoplasmSoft Tissue Neoplasm
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 60
- Registration Number
- NCT07062003
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
- Conditions
- Endometrial CarcinomaEndometrial High Grade Endometrioid AdenocarcinomaStage II Endometrial CancerStage III Endometrial CancerStage IV Endometrial Cancer
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 100
- Registration Number
- NCT07062016
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
- Conditions
- LymphomaSarcoma
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 250
- Registration Number
- NCT07058064
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study of Carbon 13-based Deep Labelling of Bone Marrow Cells
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS)Non-IgM Monoclonal Gammopathy of Undetermined Significance
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT07057583
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
- Conditions
- ObesityMenopause
- Interventions
- Drug: semaglutide or tirzepatideBehavioral: Lifestyle modification intervention
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT07057310
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 609
- Next
News
GLP-1 Receptor Agonists Naturally Restore Testosterone Levels in Men with Obesity and Type 2 Diabetes
A retrospective study of 110 men with obesity or Type 2 diabetes found that GLP-1 receptor agonists like semaglutide and tirzepatide can naturally restore testosterone levels over 18 months of treatment.
Exactech Receives FDA Clearance for First-to-Market Scapula Reconstruction System Targeting Post-Surgical Fractures
Exactech's Equinoxe Scapula Reconstruction System has received FDA 510(k) clearance as the first device specifically designed to treat acromial and scapular spine fractures following reverse total shoulder arthroplasty.
ALS Community Files Citizens' Petition Seeking FDA Approval for NurOwn Stem Cell Therapy
A coalition of ALS patients and families has filed a 309-page Citizens' Petition with the FDA requesting approval of NurOwn, a neurotrophically-enhanced stem cell therapy developed by BrainStorm Cell Therapeutics.
Precisio Biotix Achieves First-in-Human Dosing of ClyO Lysin for Multi-Drug Resistant Prosthetic Joint Infection
Precisio Biotix Therapeutics successfully administered its first-in-human dose of ClyO (LYSG101), a staph lysin, to a patient with a multi-drug resistant prosthetic joint infection under FDA compassionate care approval.
Biomerica Appoints Scott Madel as Chief Commercial Officer to Drive inFoods IBS Test Commercialization
Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.
LifePlus Achieves Clinical Validation for Revolutionary Non-Invasive Glucose and Blood Pressure Monitoring Device
LifePlus announced clinical validation of LifeLeaf®, the world's first non-invasive wearable for continuous glucose and blood pressure tracking, tested at Mayo Clinic, Cleveland Clinic, and other global centers.
EHA 2025 Showcases Breakthrough Therapies for Hematologic Malignancies
The 2025 European Hematology Association Congress featured promising clinical trial results across multiple hematologic cancers, with novel trispecific and bispecific antibodies showing exceptional response rates in challenging patient populations.
32 Biosciences Secures $6 Million Funding to Advance Gut Microbiome Diagnostic and Therapeutic Platform
32 Biosciences raised $6 million in funding to advance its AI-powered gut microbiome diagnostic platform and first-of-its-kind non-antibiotic antimicrobial therapy.
Roche's Tecentriq Cuts Colon Cancer Recurrence by 50% in Patients with DNA Repair Defects
Roche's immunotherapy drug Tecentriq combined with chemotherapy reduced cancer recurrence and death by 50% in colon cancer patients with deficient DNA mismatch repair tumors.
Enterome Reports Positive Phase 2 Data for EO2463 in Indolent Non-Hodgkin Lymphoma
Enterome will present positive Phase 2 data for EO2463, its lead OncoMimics immunotherapy, in treating indolent non-Hodgkin lymphoma at the International Conference on Malignant Lymphoma on June 21, 2025.